Survival Outcomes After Radiotherapy for the Treatment of Synchronous Oligometastatic Prostate Cancer

Menée sur la période 2011-2021 auprès de 43 patients atteints d'un cancer de la prostate oligométastatique synchrone (âge moyen : 66,7 ans), cette étude analyse la survie sans progression biochimique après une radiothérapie

Résumé en anglais

With improvement in imaging for prostate cancer, diagnosis of oligometastatic disease has substantially increased, and questions concerning metastasis-directed therapy for biochemical progression-free survival (bPFS) and overall survival have surfaced. Evidence suggests ablative radiotherapy may delay disease progression and defer systemic therapies. However, previous explorations have focused on metachronous metastases, with no substantial data on synchronous metastases. The present cohort study sought to assess bPFS among patients receiving radiotherapy for synchronous oligometastatic prostate cancer.